Cytotoxicity of ethanolic extracts of Artemisia annua to Molt-4 human leukemia cells.
Scientific exploration of artemisinin as a possible remedy for cancer
Leukemia in humansIn another study dr.Lai found very significant discovery about the leukemia cells. He found out that the cancer cells are destroyed very quickly within a few hours when they are exposed to holotransferrin (it binds receptors that serve the transfer of iron) and dihydroartemisinin (type of artemisinin which is soluble in water). He pointed out that the destruction of cells could be a product of the high concentration of iron in the leukemia cells.
(H.Lai and NP Sign, selective cancer cells exposed to dihydroartemisinin and holotransferrin)
Leukemia and lung cancer
Researchers have discovered a new type of compound that can destroy cancer cells after modifying artemisinin. This new derivative contains cyano and aryl groups, and this compound was highly effective in destroying the cancer, lung cancer and leukemia.
(Li Ying, et al, Novel antitumor artemisinin derivatives targeting the G1 phase of the cell cycle, Bioorganic and Medicinal Chemistry Letters 11: 5-8, 2001)
I hope you found some interesting information from these scientific studies on artemisinin, its derivatives and the impact of some of the cancer.
You can also read Artemisinin derivative of sweet wormwood and its growing importance in medicine.
http://artemisinine.net/news/scientific-exploration-of-artemisinin-as-a-possible-remedy-for-cancer.html
Artemisinin Mefloquine Combination for Leukemia
http://jeffreydachmd.com/2016/04/artemisinin-mefloquine-leukemia/
Figure 9E from Yang et al. Artemisinin enters cancer cell along with iron loaded ferritin. Both enter the lysosome which then triggers mitochondria reactive oxygen species (ROS) and caspase 3 programmed cell death.(6)
http://jeffreydachmd.com/2016/02/artemisinin-our-ultimate-cancer-weapon-a-gift-from-china/
TREATMENT OF LEUKEMIA WITH ARTEMISININ DERIVATIVES AND COMBINATIONS WITH OTHER ANTINEOPLASTIC AGENTS
Methods
of treating cancer, such as leukemia, via administration of
therapeutically effective amounts of artemisinins and second agents are
detailed herein. The artemisinins include
artesunate, dihydroartemisinin, artemether, arteether, artelinate, and
ART-838. The second agents include BCL-2 inhibitors such as ABT-199,
ABT-263, and ABT-737; kinase inhibitors such as lestaurtinib,
midostaurin, and sorafenib; and anti-neoplastic agents such as
cytarabine, doxorubicin, etoposide, cyclophosphamide, triplotide,
vinorelbine, cisplatin, and rituximab.
